WASHINGTON, April 4 (Reuters) - VaxGen Inc. (VXGN.PK: Quote, Profile, Research) exaggerated the benefits of its experimental anthrax vaccine at a recent annual meeting on government research, U.S. health regulators said in a warning letter released on Tuesday.
